

CONSOLIDATED					STANDALONE			
Quarter Ended on 31 st December 2011	Quarter Ended on 30 th September 2011	Nine months Ended on 31 st December 2011	Year Ended on 31 st March 2011	Particulars	Quarter Ended on 31 st December 2011	Quarter Ended on 30 th September 2011	Nine months Ended on 31 st December 2011	Year Ended on 31 st March 2011
(Reviewed)	(Reviewed)	(Reviewed)	(Audited)		(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
21766	24902	67391	78805	1 (a) Net Sales / Income from Operations	21766	24902	67391	78805
16516	14903	45168	41859	Domestic	13294	13616	38461	38147
38282	39805	112559	120664	Exports	35060	38518	105852	116952
149	109	403	766	Total	149	109	403	766
38133	39696	112156	119898	Less : Excise Duty	34911	38409	105449	116186
79	103	222	306	Net Sales / Income from Operations	79	103	222	306
				(b) Other Operating Income				
38212	39799	112378	120204	Total Income	34990	38512	105671	116492
250	(2,085)	(3,009)	(472)	2 Expenditure	250	(2,085)	(3,009)	(472)
12916	15422	40140	43494	(a) Decrease/(increase) in stock in trade and work in progress	12916	15422	40140	43494
5774	6038	18357	16018	(b) Consumption of Raw Materials & Packing Materials	3272	4841	12669	12857
3982	3715	11642	14149	(c) Purchase of traded goods	3982	3715	11642	14149
909	1309	3427	4714	(d) Employees' Cost	909	1309	3427	4714
(37)	243	198	664	(e) Research and Development Expense	(37)	243	198	664
7570	9110	23693	25612	(f) Excise Duty	7672	9017	23598	25513
				(g) Other Expenditure				
31364	33752	94448	104179	Total	28964	32462	88665	100919
6848	6047	17930	16025	3 Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	6026	6050	17006	15573
13	10	31	8	4 Other Income	13	10	31	8
6861	6057	17961	16033	5 Profit/(Loss) before Interest, Depreciation, & Exceptional Items	6039	6060	17037	15581
809	845	2473	2959	6 Depreciation	809	845	2473	2959
698	708	2083	2389	7 Interest (Net)	698	708	2083	2389
5354	4504	13405	10685	8 Profit/(Loss) after Interest but before Exceptional Items	4532	4507	12481	10233
964	910	2597	1864	9 Tax Expense	864	917	2492	1801
(33)	(210)	(175)	282	Less : Provision for Current Tax	(33)	(210)	(175)	282
4423	3804	10983	8539	(Less)/Add : Provision for Deferred Tax (Liability)/Assets	3701	3800	10164	8150
3770	3770	3770	3770	10 Net Profit / (Loss) from Ordinary Activities after Tax	3770	3770	3770	3770
-	-	-	25758	11 Paid up Equity Share Capital	-	-	-	23851
2.35	2.02	5.83	4.53	(Face value of share Rs 2/-)	1.96	2.02	5.39	4.32
48763089	48763089	48763089	48763089	12 Reserves excluding Revaluation Reserve	48763089	48763089	48763089	48763089
25.87	25.87	25.87	25.87	13 Basic & Diluted EPS (Not Annualised)	25.87	25.87	25.87	25.87
139752825	139752825	139752825	139752825	14 Public Shareholding	139752825	139752825	139752825	139752825
100.00	100.00	100.00	100.00	- Number of Shares	100.00	100.00	100.00	100.00
74.13	74.13	74.13	74.13	- Percentage of Shareholding	74.13	74.13	74.13	74.13
				15 Promoters and Promoter Group Shareholding				
				Fully Non - Encumbered				
				Number of Shares				
				Percentage of Shares (as a % of the total shareholding of promoter and promoter group)				
				Percentage of Shares (as a % of the total share capital of the Company)				

Notes :

- 1 The above results, which includes unaudited results of the Subsidiary, have been duly reviewed by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website viz www.alembic-india.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com)
- 2 This being the first year of the Company after the demerger becoming effective on 1st April, 2011, the comparable figures for the corresponding quarter/nine months period of the previous financial year were not published. However, the numbers provided in the information memorandum filed with the stock exchanges after receiving Order from the Hon'ble High Court approving the Scheme of demerger are produced below for comparison purpose.

(Rs.in Laacs)		
Particulars	For the Nine months ended on 31.12.11	For the Nine months ended on 31.12.10
Sales	112559	90891
EBIDTA	17930	13311
PBT	13405	9382
PAT	10983	7511

- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 4 Details of Investor's Complaints for the quarter ended on 31st December, 2011 : Unresolved at the beginning of the quarter-NIL Received during the quarter-12, Disposed off during the quarter-12, Unresolved at the end of the quarter - Nil

For Alembic Pharmaceuticals Limited

Place : Vadodara
Date : 8th Feb, 2012

Chirayu Amin
Chairman and Managing Director

Visit us at www.alembic-india.com